Biotech2050’s Post

Excited to share the latest Biotech2050 podcast episode with Ken Keller, President and CEO of Daiichi Sankyo US. We explored the evolution of the antibody drug conjugate space and discussed Daiichi Sankyo’s strategic shift from cardiology to oncology. Ken shared his perspective on the critical role of partnerships in driving innovation and progress in today's landscape. We also delved into how operating within a diverse, cross-cultural framework enhances organizational success. Listen now using the link below and join the conversation! #Biotech2050 #podcast #biotech #oncology #innovation #cancertreatment #adcs #antibodies #HER2

Join Rahul Chaturvedi, CEO of Clora, as he chats with Ken Keller, President and CEO of Daiichi Sankyo US, on a new episode of the Biotech2050 podcast. Ken shares insights into Daiichi’s strategic pivot to oncology, their industry-leading breakthroughs in antibody-drug conjugates (ADCs), and the success of their HER2-targeted therapies. He also discusses the power of strategic partnerships, building a passionate, impact-driven team, and his visionary perspective on the future of cancer treatments. Listen now using the link below. #Clora #podcast #biotech #oncology #leadership #cancertreatment #adcs #antibodies #HER2

Hear from IQVIA Biotech’s Global Head of Oncology Gerhard du Toit, together with Murray Aitken, executive director of the IQVIA Institute for Human Data Science as they address global oncology trends and how they stand to impact sponsors preparing for early and late phase oncology trials. Watch on-demand: https://bit.ly/3V8RtNU #oncology #biotech #oncologytrends #earlyphase #CancerResearch #ClinicalTrials #diversity #trialdesign

Hear from IQVIA Biotech’s Global Head of Oncology Gerhard du Toit, together with Murray Aitken, executive director of the IQVIA Institute for Human Data Science as they address global oncology trends and how they stand to impact sponsors preparing for early and late phase oncology trials. Watch on-demand: https://bit.ly/3ApJS5X #oncology #biotech #oncologytrends #earlyphase #CancerResearch #ClinicalTrials #diversity #trialdesign

Hear from IQVIA Biotech’s Global Head of Oncology Gerhard du Toit, together with Murray Aitken, executive director of the IQVIA Institute for Human Data Science as they address global oncology trends and how they stand to impact sponsors preparing for early and late phase oncology trials. Watch on-demand: https://bit.ly/4doNsw8 #oncology #biotech #oncologytrends #earlyphase #CancerResearch #ClinicalTrials #diversity #trialdesign

In these two podcast episodes, GI oncologists use clinical cases of gastric and gastroesophageal (GE) cancer to demonstrate the application of treatment sequences, biomarker testing, and practice-changing data. In Episode 1, Dr. Samuel Klempner Dr. Elizabeth Smyth focus on a patient with non-metastatic cancer, while Episode 2 looks at a metastatic case, covering the latest developments in the field. Listen to both podcast episodes: https://lnkd.in/eR3XNAN4 Or listen on Spotify, Apple, or Google Podcasts. #MedEd #FreeMedEd #MedicalEducation #Oncology

The pace of innovation in oncology is in constant flux. From the expansion of CAR-Ts, to growth in precision medicine and the identification of new biomarkers—all of these changes demand new analytics strategies. ZS’s Jeevarasan Elanchelvan, Christina Corridon and Deepika Sinha highlight some of the biggest opportunities for pharma to grow their analytics capabilities to meet today’s challenges in the oncology landscape. #oncology #analytics

Novartis amplifies radiopharmaceuticals presence with Mariana Oncology's $1B acquisition. A pivotal move for Novartis, signaling a deepened commitment to cancer treatments with Mariana's cutting-edge actinium-platform. 🧬✨ The strategic buy enriches Novartis' radioligand array and fuels innovative paths for patient care. With an already robust pipeline, this deal unlocks a broader spectrum of therapeutic possibilities. 🔬 🤝 Novartis' expertise in bringing drugs to market paired with Mariana's novel radioisotopes primes the duo for groundbreaking impacts in oncology. #Novartis #MarianaOncology #OncologyInnovation

Hear from IQVIA Biotech’s Global Head of Oncology Gerhard du Toit, together with Murray Aitken, executive director of the IQVIA Institute for Human Data Science as they address global oncology trends and how they stand to impact sponsors preparing for early and late phase oncology trials. Watch on-demand: https://bit.ly/3FK7hhN #oncology #biotech #oncologytrends #earlyphase #CancerResearch #ClinicalTrials #diversity #trialdesign

The pace of innovation in oncology is in constant flux. From the expansion of CAR-Ts, to growth in precision medicine and the identification of new biomarkers—all of these changes demand new analytics strategies. ZS’s Jeevarasan Elanchelvan, Christina Corridon and Deepika Sinha highlight some of the biggest opportunities for pharma to grow their analytics capabilities to meet today’s challenges in the oncology landscape. #oncology #analytics